Empirical Antibiotic Treatment of Community-Acquired Pneumonia |
Outpatients - Previously healthy and no antibiotics in past 3 months
- Comorbidities or antibiotics in past 3 months: select an alternative from a different class
- In regions with a high rate of high-level pneumococcal macrolide resistance,b consider alternatives listed earlier for pts with comorbidities.
|
Inpatients, Non-ICU - A respiratory fluoroquinolone (e.g., moxifloxacin [400 mg PO or IV qd] or levofloxacin [750 mg PO or IV qd])
- A β-lactamc (e.g., ceftriaxone [1-2 g IV qd], ampicillin [1-2 g IV q4-6h], cefotaxime [1-2 g IV q8h], ertapenem [1 g IV qd]) plus a macrolided (e.g., oral clarithromycin or azithromycin as listed earlier or IV azithromycin [1 g once, then 500 mg qd])
|
Inpatients, ICU - A β-lactame (e.g., ceftriaxone [2 g IV qd], ampicillin-sulbactam [2 g IV q8h], or cefotaxime [1-2 g IV q8h]) plus either azithromycin or a fluoroquinolone (as listed earlier for inpatients, non-ICU)
|
Special Concerns If Pseudomonas is a consideration: - An antipseudomonal β-lactam (e.g., piperacillin/tazobactam [4.5 g IV q6h], cefepime [1-2 g IV q12h], imipenem [500 mg IV q6h], meropenem [1 g IV q8h]) plus either ciprofloxacin (400 mg IV q12h) or levofloxacin (750 mg IV qd)
- The earlier β-lactams plus an aminoglycoside (amikacin [15 mg/kg qd] or tobramycin [1.7 mg/kg qd]) plus azithromycin
- The earlier β-lactamsf plus an aminoglycoside plus an antipneumococcal fluoroquinolone
If CA-MRSA is a consideration: |